PROTOKOLwiki
COMPOUNDS / STEROID / TESTOSTERONE PROPIONATE
STEROID

TESTOSTERONE PROPIONATE

HIGH RISK
BEST FOR:Hormone Replacement●●●●●●●○○○7/10
TESTOSTERONE PROPIONATE · TEST PROP · TP · TESTOVIRON · PROPIONATE · TESTEX · ANDROGENEX · ANERTAN
Anabolic SteroidTestosterone EsterTRTShort-ActingInjectableAndrogen

Short-acting injectable testosterone ester used in TRT and performance enhancement, requiring frequent administration.

ROUTE / DOSAGE
LOW25mg
STANDARD50-100mg
HIGH200mg
Note: Less common than IM but viable; slower release profile
CYCLE
Every 2-3 days IM/SubQ daily transdermal. TRT cycles typically 8-12 weeks under medical supervision.
BIOAVAILABILITY
~100% IM ~100% SubQ ~10% transdermal
ACTIVE DURATION
2-3 days (subjective)
STORAGE
Room temperature (15-25°C) protect from light do not freeze keep in original sealed vial
HALF-LIFE
0.8-1.6 days (plasma)
DURATION BREAKDOWN
Total3-4 days
Onset1-2 days
Come up1-2 days
Peak1-2 days
Offset1-2 days
After effects2-3 days
Duration varies by route, dose, and individual. Source: community reports.
§ 01 — EFFECTS
8 documented
Increased muscle mass and strength
Enhanced nitrogen retention
Improved recovery
Increased libido and sexual function
Erythropoiesis stimulation
Androgenic effects (body hair, deepening voice)
Mood elevation
Water retention
§ 02 — RISKS
Suppression of endogenous testosterone production (HPTA shutdown)
Cardiovascular strain including dyslipidemia and hypertension
Prostatic hyperplasia and potential acceleration of prostate pathology
Gynecomastia via aromatization to estradiol
Hepatic stress (less than oral steroids but possible)
Virilization in women (irreversible deepening voice, clitoromegaly)
§ 03 — INTERACTIONS
Interaction data not yet available for this compound.
§ 04 — SCIENCE

Testosterone propionate is one of the oldest testosterone esters, clinically used for male hypogonadism and historically for breast cancer in women. In vitro studies show it promotes proliferation of bone marrow mesenchymal stem cells without altering differentiation capacity. Animal models routinely use TP to induce benign prostatic hyperplasia, confirming potent androgenic activity on prostate tissue. Its short half-life necessitates frequent dosing, making it less convenient than longer esters (cypionate, enanthate) for TRT. Evidence for performance enhancement is largely observational; controlled trials in athletic populations are limited due to ethical constraints.

§ 06 — SOURCES
[1]
Testosterone Propionate Promotes Proliferation and Viability of Bone Marrow Mesenchymal Stem Cells
pubmed.ncbi.nlm.nih.gov ↗
[2]
Comparative application of testosterone undecanoate and/or testosterone propionate in induction of BPH in Wistar rats
pubmed.ncbi.nlm.nih.gov ↗
[3]
Inhibitory Effect of Artemisinin on Testosterone Propionate Induced Benign Prostatic Hyperplasia
pubmed.ncbi.nlm.nih.gov ↗
[4]
Effect of Veratrum maackii on Testosterone Propionate-Induced Benign Prostatic Hyperplasia in Rats
pubmed.ncbi.nlm.nih.gov ↗
[5]
Testosterone Propionate Therapy in Breast Cancer (JAMA 1964)
pubmed.ncbi.nlm.nih.gov ↗
[6]
Effects of Taraxaci Herba (Dandelion) on Testosterone Propionate-Induced BPH in Rats
pubmed.ncbi.nlm.nih.gov ↗
[7]
Classification and detection of testosterone propionate and nandrolone residues in duck meat using SERS
pubmed.ncbi.nlm.nih.gov ↗
[8]
Analysis of Methyltestosterone and Testosterone Propionate in Dried Blood Spots After Transdermal Application
pubmed.ncbi.nlm.nih.gov ↗
Disclaimer. Protokol.wiki is an informational reference. Nothing on this site is medical advice. Compounds listed may be unapproved, unregulated, or illegal in your jurisdiction. Consult a licensed physician before use. Data compiled from peer-reviewed literature.
METHODOLOGYCONTRIBUTECONTACT